LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII.
about
The epidermal growth factor receptor variant III (EGFRvIII): where wild things are alteredThe LRIG family: enigmatic regulators of growth factor receptor signaling.MicroRNA-19a promotes glioma cell growth by repressing LRIG1LRIG1 as a potential novel marker for neoplastic transformation in ocular surface squamous neoplasiaTherapeutic control and resistance of the EGFR-driven signaling network in glioblastoma.Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERα-positive breast cancer.LRIG and cancer prognosis.LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signalingIntracellular LINGO-1 negatively regulates Trk neurotrophin receptor signaling.Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth.LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells.Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3).The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status.Expression of LRIG1 is associated with good prognosis and human papillomavirus status in oropharyngeal cancer.Intestinal stem cells - types and markers.LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor.The role of ubiquitin-proteasome system in glioma survival and growth.The shaping of invasive glioma phenotype by the ubiquitin-proteasome system.EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy.Non-Small Cell Lung Cancer Radiogenomics Map Identifies Relationships between Molecular and Imaging Phenotypes with Prognostic Implications.Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro.LRIG1 improves chemosensitivity through inhibition of BCL-2 and MnSOD in glioblastoma.Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody.HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity.LRIG1 inhibits STAT3-dependent inflammation to maintain corneal homeostasis.A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk.Feedback regulation of RTK signaling in development.FHL2 interacts with EGFR to promote glioblastoma growth.Lrig1 is a haploinsufficient tumor suppressor gene in malignant glioma.Downregulation of leucine-rich repeats and immunoglobulin-like domains 1 by microRNA-20a modulates gastric cancer multidrug resistance.LRIG1 negatively regulates RET mutants and is downregulated in thyroid cancer.LRIG1 modulates aggressiveness of head and neck cancers by regulating EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling.Essential Role of Linx/Islr2 in the Development of the Forebrain Anterior Commissure.
P2860
Q27015045-0D683164-AE09-4CEB-B095-F0FA11FA90AFQ34276176-91E13527-51C6-4551-9928-45BC3A48692AQ35017058-B7F530B8-235D-4097-8AC1-B10F0BB64CCEQ35141723-115E0C88-A47D-425A-BEBE-170AB2F070FAQ35341639-8D05BFBC-BB8F-4228-AFF7-EC0709D48F7DQ35386137-47D1E3AC-A7C1-4887-AE82-D6648C4E3A14Q35626430-841EC6F9-B295-4912-9AC0-7ECC1FC133E8Q35803259-23389B9A-6852-4A5F-A2DC-92AA1B89928FQ36421275-A757AE02-DED0-49C1-95CB-72A7485A30F5Q36437261-4EE05FF3-B212-49B7-9D39-D505920D6B3BQ36723368-CD24150A-45B4-496D-B189-4D609C067EE3Q37003688-56D735E4-228D-4632-942E-EE34DA54BA21Q37048337-A82E4486-B8BA-4971-93A0-8566F5F62124Q37109236-AEBBDE47-2F96-415A-869C-CDEC91E1F163Q37681779-8FF3F19B-69EC-4442-8145-25B1DE7D5D0DQ38087571-7E5B85AD-C16F-4D00-8A0C-A39FE14F7E76Q38096295-76EBD739-E7F9-4F99-922C-EB188975D4A4Q38107999-3C2512C2-8E98-48FC-8977-696F07601C15Q38134142-E53030EC-7785-4B43-9826-1D99969643BCQ38199643-8430CA69-CDFF-491E-ABBC-4FCF73EFCDF1Q38373627-A58C6FC8-0453-4F71-9CB2-AE616A10F91EQ38755339-4C80FAB5-A349-4AC3-9569-E51EE1135E76Q38935017-E2810AF5-8A16-488A-8310-BADE9C86ABBBQ39233148-FD4226E6-1C94-482D-94E0-0A340B9DCABBQ39368710-70AE2A2E-E4B9-4AFB-9CB3-51802F91E479Q39574128-0BA0B5D8-97A6-455A-8425-ED283D07A16BQ42450624-E54F67D2-F556-4EFD-8D7C-C518F8E98E0BQ43072092-A3C6C2C2-D38D-40C7-BA31-174938EC9CFFQ46578462-A106943A-17C3-4BF2-BBB1-B0B8A02C190CQ47871595-6AE68390-3B3C-441D-A78B-6115E02C67C7Q49390262-40A2E27C-7F37-4DBE-B0F2-7FEE71578248Q49945042-55CA95A1-C83A-40EB-A566-E3D4F7398CEFQ50047531-FC042FB6-6340-411A-8CE1-C317B06572D8Q51034812-08433DF2-520F-4BAD-A705-A8DF2571B234Q54979521-9620C3EB-F414-49AE-B288-6E64F81D3FC3
P2860
LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII.
@en
type
label
LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII.
@en
prefLabel
LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII.
@en
P2093
P2860
P356
P1433
P1476
LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII.
@en
P2093
D L Shattuck
K L Carraway
M B Laederich
P2860
P2888
P304
P356
10.1038/ONC.2008.185
P407
P577
2008-06-09T00:00:00Z
P5875
P6179
1016561770